Leaflet: information for the user
DEFLAZACORT ALTER 6 mg tablets EFG
Read this leaflet carefully before you start taking the medicine.
|
1. What DEFLAZACORT ALTER 6 mg tablets are and what they are used for
2. Before taking DEFLAZACORT ALTER 6 mg tablets
3. How to take DEFLAZACORT ALTER 6 mg tablets
4. Possible side effects
5. Storage of DEFLAZACORT ALTER 6 mg tablets
6. Additional information
DEFLAZACORT ALTER 6 mg tablets belongs to a group of medicines called systemic corticosteroids.
DEFLAZACORT ALTER 6 mg tablets is indicated for the treatment of:
Do not take DEFLAZACORT ALTER 6 mg tablets:
Be especially careful with DEFLAZACORT ALTER 6 mg tablets:
Taking other medications:
Inform your doctor or pharmacist if you are taking, or have recently taken, any other medication, including those acquired without a prescription.
In particular, inform your doctor or pharmacist if you are taking:
Do not take any of these medications at the same time as DEFLAZACORT ALTER 6 mg tablets without your doctor's knowledge.
Use in athletes:
Inform patients that this medication contains deflazacort, which may produce a positive result in doping control tests.
Pregnancy:
Consult your doctor or pharmacist before taking a medication.
Human experience is limited, so DEFLAZACORT ALTER 6 mg tablets should only be used in cases where a risk-benefit assessment recommends their use.
Breastfeeding:
Consult your doctor or pharmacist before taking a medication.
Deflazacort is excreted in breast milk, so its use is not recommended during breastfeeding.
Driving and operating machinery:
No effects on the ability to drive and operate machinery have been described.
Important information about some of the components of DEFLAZACORT ALTER 6 mg tablets:
This medication contains lactose. If your doctor has indicated that you have a certain sugar intolerance, consult with them before taking this medication.
Follow these instructions unless your doctor has given you different instructions. Remember to take the medication.
The tablets should be swallowed whole, without chewing, with a little liquid.
Adults:
The dose should be individualized. Therefore, the number and frequency of tablets that you should take will be determined by your doctor based on the type and severity of your disease, as well as your response to treatment. In adults, the dose can range from 6 to 90 mg per day and in children from 0.25 to 1.15 mg/kg. It is essential that you understand your doctor's instructions regarding the administration of the medication and, in case of doubt, do not hesitate to consult them.
Your doctor will indicate the duration of treatment. Do not stop it before, nor without authorization, and never do it abruptly.
In special situations (stress, major infections, severe trauma, or surgical interventions) it may be necessary to adjust the dose. Consult with your doctor to explain the course of action to follow in these cases.
After prolonged treatment, the administration of this medication should never be stopped abruptly. Your doctor will indicate how to gradually reduce the dose. It is also essential that you maintain contact with your doctor at the end of treatment to act in case of reappearance of symptoms.
If you take more DEFLAZACORT ALTER 6 mg tablets than you should:
If you have taken more medication than you should, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take DEFLAZACORT ALTER 6 mg tablets:
Do not take a double dose to compensate for the missed doses.
Effects that occur when treatment with DEFLAZACORT ALTER 6 mg tablets is interrupted:
Prolonged treatments that are stopped abruptly may cause: fever, discomfort, and muscle and joint pain.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medicines, DEFLAZACORT ALTER 6 mg tablets may cause side effects, although not everyone will experience them.
In short-term treatments, this medicine is well tolerated and side effects are very rare. However, in prolonged treatments, the following have been observed:
The following side effects have also been reported at an unknown frequency: Blurred vision.
During treatment with this medicine, your tendency to infections may increase, so if you notice any symptoms of illness that may be related to taking this medicine, contact your doctor.
Similarly, if any of the reactions described above appear or you observe any other not described in this leaflet, consult your doctor or pharmacist.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es/. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the reach and sight of children.
No special storage conditions are required.
Expiration Date:
This medication should not be used after the expiration date indicated on the packaging. The expiration date is the last day of the month indicated.
Do not dispose of medications through the drains or trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point(or any other medication waste collection system) at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of DEFLAZACORT ALTER 6 mg tablets
The active ingredient is deflazacort.
The other components are: Lactose, microcrystalline cellulose, cornstarch and magnesium stearate.
Appearance of the product and contents of the package
Oral tablets, circular and off-white in color.
Deflazacort Alter 6 mg tablets are presented in packages containing 20 or 500 tablets.
Holder of the marketing authorization
Laboratorios Alter, S.A.
Mateo Inurria, 30
28036 Madrid
Responsible for manufacturing
LACER, S.A. ; C/ Boters 5. Parc Tecnologic del Vallés (Cerdanyola del Vallés) -08290-Spain
Date of the last review of this leaflet: September 2017
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.